Bio-Techne Corp (TECH) Stock

Bio-Techne Corp trades at a P/E ratio of 105.67, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 27.03 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.74 suggests the stock may be undervalued relative to its growth rate.

With a beta of 1.48, Bio-Techne Corp is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 4.50 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Bio-Techne Corp achieves a profit margin of 6.67%, meaning it retains $6.67 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 19.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 3.97% and ROA at 6.52%, the company achieves moderate returns on invested capital.

Bio-Techne Corp's revenue declined by 0.40% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings increased by 9.10% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Bio-Techne Corp offers a dividend yield of 0.57%, paying $0.32 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Feb 13, 2026.

The dividend sustainability can be assessed through the payout ratio - Bio-Techne Corp pays $0.32 per share in dividends against earnings of $0.51 per share, resulting in a payout ratio of 62.75%. This high payout ratio of 60-90% leaves limited earnings for reinvestment. While currently sustainable, there's less buffer for dividend growth or protection during earnings downturns. The next dividend payment is scheduled for Feb 27, 2026.

Bio-Techne Corp has a market capitalization of $8.4B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 156.45M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.

Bio-Techne Corp's book value per share is $12.90, while the current stock price is $50.85, resulting in a price-to-book (P/B) ratio of 3.94. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

15 analysts cover TECH with 73% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $75.25 implies 48.0% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:1 Strong Buy, 10 Buy, 4 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.